Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein

NCT02364479 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Spondyloarthritis

Interventions

DRUG: 50mg Yisaipu
DRUG: 25mg etanercept
DRUG: Placebo

Sponsor

Sun Yat-sen University